research use only
Cat.No.S3856
|
In vitro |
DMSO
: 7 mg/mL
(44.27 mM)
|
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 158.12 | Formula | C4H6N4O3 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 97-59-6 | -- | Storage of Stock Solutions |
|
|
| Synonyms | Glyoxyldiureide, 5-Ureidohydantoin | Smiles | C1(C(=O)NC(=O)N1)NC(=O)N | ||
| In vivo |
The subchronic administration of allantoin (1, 3 or 10 mg/kg, for 7 days) significantly increases the latency time measured during the passive avoidance task in scopolamine-induced cholinergic blockade and normal naïve mice. This compound treatment (3 or 10 mg/kg, for 7 days) also increases the expression levels of phosphorylated phosphatidylinositide 3-kinase (PI3K), phosphorylated protein kinase B (Akt) and phosphorylated glycogen synthase kinase-3β (GSK-3β). It has memory-enhancing effects, and these effects may be partly mediated by the PI3K-Akt-GSK-3β signal pathway.
|
References |
|
|---|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06338410 | Completed | Kangaroo Mother Care|Oxidative Stress |
University of Health Sciences Lahore|Services Hospital Lahore |
August 1 2023 | Not Applicable |
| NCT04325490 | Completed | Intertrigo |
Mahidol University|HOE pharmaceuticals Sdn. Bhd. |
October 1 2019 | Phase 4 |
| NCT04046783 | Completed | Cesarean Section; Dehiscence|Scar Keloid|Wound Heal |
University of Salerno |
March 2 2019 | -- |
| NCT03849677 | Completed | Healthy|Diet Modification |
Erasme University Hospital|Fonds National de la Recherche Scientifique|Fonds Erasme|Fonds pour la chirurgie cardiaque |
March 10 2019 | -- |
| NCT03631394 | Completed | Exercise |
Loma Linda University |
September 1 2018 | Not Applicable |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.